Beta-aminoketones as prodrugs for selective irreversible inhibitors of type-1 methionine aminopeptidases. 2014

Markus Altmeyer, and Eberhard Amtmann, and Carina Heyl, and Aline Marschner, and Axel J Scheidig, and Christian D Klein
Medicinal Chemistry, Institute of Pharmacy and Molecular Biotechnology, IPMB, Heidelberg University, Im Neuenheimer Feld 364, 69120 Heidelberg, Germany.

We identified and characterized β-aminoketones as prodrugs for irreversible MetAP inhibitors that are selective for the MetAP-1 subtype. β-Aminoketones with certain structural features form α,β-unsaturated ketones under physiological conditions, which bind covalently and selectively to cysteines in the S1 pocket of MetAP-1. The binding mode was confirmed by X-ray crystallography and assays with the MetAPs from Escherichia coli, Staphylococcus aureus and both human isoforms. The initially identified tetralone derivatives showed complete selectivity for E. coli MetAP versus human MetAP-1 and MetAP-2. Rational design of indanone analogs yielded compounds with selectivity for the human type-1 versus the human type-2 MetAP.

UI MeSH Term Description Entries
D007659 Ketones Organic compounds containing a carbonyl group Ketone
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000626 Aminopeptidases A subclass of EXOPEPTIDASES that act on the free N terminus end of a polypeptide liberating a single amino acid residue. EC 3.4.11. Aminopeptidase
D001426 Bacterial Proteins Proteins found in any species of bacterium. Bacterial Gene Products,Bacterial Gene Proteins,Gene Products, Bacterial,Bacterial Gene Product,Bacterial Gene Protein,Bacterial Protein,Gene Product, Bacterial,Gene Protein, Bacterial,Gene Proteins, Bacterial,Protein, Bacterial,Proteins, Bacterial
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.

Related Publications

Markus Altmeyer, and Eberhard Amtmann, and Carina Heyl, and Aline Marschner, and Axel J Scheidig, and Christian D Klein
May 2007, International journal of pharmaceutics,
Markus Altmeyer, and Eberhard Amtmann, and Carina Heyl, and Aline Marschner, and Axel J Scheidig, and Christian D Klein
June 2006, Angewandte Chemie (International ed. in English),
Markus Altmeyer, and Eberhard Amtmann, and Carina Heyl, and Aline Marschner, and Axel J Scheidig, and Christian D Klein
September 2012, Journal of medicinal chemistry,
Markus Altmeyer, and Eberhard Amtmann, and Carina Heyl, and Aline Marschner, and Axel J Scheidig, and Christian D Klein
July 2013, Journal of medicinal chemistry,
Markus Altmeyer, and Eberhard Amtmann, and Carina Heyl, and Aline Marschner, and Axel J Scheidig, and Christian D Klein
December 2011, Tuberculosis (Edinburgh, Scotland),
Markus Altmeyer, and Eberhard Amtmann, and Carina Heyl, and Aline Marschner, and Axel J Scheidig, and Christian D Klein
January 1965, Antimicrobial agents and chemotherapy,
Markus Altmeyer, and Eberhard Amtmann, and Carina Heyl, and Aline Marschner, and Axel J Scheidig, and Christian D Klein
March 2019, The Biochemical journal,
Markus Altmeyer, and Eberhard Amtmann, and Carina Heyl, and Aline Marschner, and Axel J Scheidig, and Christian D Klein
September 2014, ACS medicinal chemistry letters,
Markus Altmeyer, and Eberhard Amtmann, and Carina Heyl, and Aline Marschner, and Axel J Scheidig, and Christian D Klein
May 2019, International journal of biological macromolecules,
Markus Altmeyer, and Eberhard Amtmann, and Carina Heyl, and Aline Marschner, and Axel J Scheidig, and Christian D Klein
July 1989, Biological chemistry Hoppe-Seyler,
Copied contents to your clipboard!